Celltrion Antibody Becomes First Home-Grown COVID-19 Drug Approval In Korea
Executive Summary
Helped by government support for the development of COVID-19 drugs and vaccines, Celltrion’s monoclonal antibody becomes the first therapeutic for the disease to be officially approved in South Korea.
You may also be interested in...
Coronavirus Update: EU Demands AstraZeneca Meets Its Vaccines Commitments After Supply Warning
Plus Takeda starts vaccine trial in Japan and South Korea clears Celltrion's antibody therapeutic.
Celltrion Expands In APAC, Small Molecules Via $278m Takeda Asset Buy
In continuing strategy to shed non-core assets globally, Japanese firm will sell portfolio of selected products in Asia-Pacific to Korean biosimilars giant Celltrion.
Celltrion Accelerates Antibody, Kit Development As It Takes Coronavirus Initiative
Celltrion unveils emergency plans to deal with the COVID-19 situation in South Korea by speeding up development of a potential therapeutic antibody and rapid, accurate testing kit without considering economic returns.
Need a specific report? 1000+ reports available
Buy Reports